Department of Pediatric Infectious Disease, SBU Ankara Dr. Sami Ulus Maternity Child Health and Diseases Training and Research Hospital, Ankara, Turkey.
Division of Pediatric Intensive Care, SBU Ankara Dr. Sami Ulus Maternity Child Health and Diseases Training and Research Hospital, Ankara, Turkey.
J Paediatr Child Health. 2022 Jan;58(1):129-135. doi: 10.1111/jpc.15674. Epub 2021 Aug 3.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may result in a life-threatening hyperinflammatory condition named multisystem inflammatory syndrome in children (MIS-C). We aimed to assess demographics, clinical presentations, laboratory characteristics and treatment outcomes of patients with MIS-C.
We performed a retrospective study of patients with MIS-C managed between August 2020 and March 2021 at Dr. Sami Ulus Maternity Child Health and Diseases Training and Research Hospital in Turkey.
A total of 45 patients (23 male, 51%) with a median age of 8.7 years (interquartile range: 5.6-11.7 years) were enrolled to study. The SARS-CoV-2 serology was positive in 43 (95%) patients. Organ-system involvement included the dermatologic in 41 (91%), cardiovascular in 39 (87%), hematologic in 36 (80%) and gastrointestinal in 36 (80%) patients. Acute anterior uveitis was diagnosed in nine (20%) patients. Two patients presented with clinical findings of deep neck infection such as fever, neck pain, trismus, swelling and induration on the cervical lymph node. One patient presented with Henoch-Schonlein purpura-like eruption. Coronary artery dilatation was detected in five (11%) patients. For treatment of MIS-C, intravenous immunoglobulin was used in 44 (98%) patients, methylprednisolone in 27 (60%) and anakinra in 9 (20%) patients. The median duration of hospitalisation was nine days. All patients recovered.
Children with MIS-C might have variable clinical presentations. Acute anterior uveitis might be a prominent presentation of MIS-C and require ophthalmological examination. It is essential to make patient-based decisions and apply a stepwise approach for the treatment of this life-threatening disease.
严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染可能导致一种名为儿童多系统炎症综合征(MIS-C)的危及生命的过度炎症状态。我们旨在评估 MIS-C 患者的人口统计学、临床表现、实验室特征和治疗结果。
我们对 2020 年 8 月至 2021 年 3 月期间在土耳其萨米乌卢斯母婴健康和疾病培训与研究医院接受治疗的 MIS-C 患者进行了回顾性研究。
共有 45 名(23 名男性,51%)中位年龄为 8.7 岁(四分位距:5.6-11.7 岁)的患者入组研究。43 名(95%)患者的 SARS-CoV-2 血清学检测呈阳性。受累器官系统包括 41 名(91%)患者的皮肤、39 名(87%)患者的心血管、36 名(80%)患者的血液和 36 名(80%)患者的胃肠道。9 名(20%)患者诊断为急性前葡萄膜炎。2 名患者表现为深部颈部感染的临床特征,如发热、颈部疼痛、牙关紧闭、颈部淋巴结肿胀和硬结。1 名患者表现为过敏性紫癜样皮疹。5 名(11%)患者冠状动脉扩张。44 名(98%)患者接受静脉注射免疫球蛋白治疗,27 名(60%)患者接受甲基强的松龙治疗,9 名(20%)患者接受阿那白滞素治疗。中位住院时间为 9 天。所有患者均康复。
MIS-C 患儿可能有不同的临床表现。急性前葡萄膜炎可能是 MIS-C 的一个突出表现,需要进行眼科检查。基于患者的情况做出决策并采用逐步治疗方法治疗这种危及生命的疾病至关重要。